ArticleFrontiers of medicine2019

Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.

Xiaojun Huang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.